Keywords
Hepatitis
Chemoprevention
Quality of life
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the effects of the main drugs used in the treatment of tuberculosis, as well as their relationship with the development of liver injury in patients who use these drugs in combination, in addition to evaluating the effectiveness of chemopreventive strategies. Methods: This is a integrative review that analyzed scientific productions from the National Library of Medicine (PubMed) and Virtual Health Library (BVS) databases. Inclusion and exclusion criteria were applied for the analysis of results and discussion. Results: Antituberculosis drugs, mainly Rifampicin, Isoniazid and Pyrazinamide, have important hepatotoxic potential that have a harmful laboratory and clinical character and therefore increase the dropout rate of tuberculosis treatment, however, hepatoprotective drugs are already relevant to be used in therapy complementary to antituberculous drugs as they help in the reduction of symptoms and complications, reducing the dropout rate and improving patients' quality of life. Final considerations: There is a clear need to add drugs to the RHZE regimen that are hepatoprotective, mainly bicyclol, silymarin and N-acetylcysteine.
References
AZUMA J, et al. NAT2 Genotype Guided Regimen Reduces Isoniazid-Induced Liver Injury and Early Treatment Failure in the 6-Month Four-Drug Standard Treatment of Tuberculosis: A Randomized Controlled Trial for Pharmacogenetics-Based Therapy. European Journal of Clinical Pharmacology, 2013; 69(5): 1091-1101.
BLIVEN-SIZEMORE EE, et al. Three Months of Weekly Rifapentine plus Isoniazid Is Less Hepatotoxic than Nine Months of Daily Isoniazid for LTBI. The International Journal of Tuberculosis and Lung Disease, 2015; 19(9): 1039-1044.
CHEN G, et al. Association of UGT2B7 Polymorphisms with Risk of Induced Liver Injury by Anti-Tuberculosis Drugs in Chinese Han. International Journal of Immunopathology and Pharmacology, 2017; 30(4): 434-438.
CHEN R, et al. Associação de Polimorfismos em Genes Transportadores de Drogas (SLCO1B1 e SLC10A1) e Hepatotoxicidade Induzida por Drogas Anti-Tuberculose em uma Coorte Chinesa. Tuberculose, 2015; 95(1): 68-74.
CHEN Y, et al. Pharmacoeconomics of Three Therapeutic Schemes for Anti-Tuberculosis Therapy Induced Liver Injury in China. Open Medicine, 2018; 13(1): 53-63.
CHU NH, et al. Role of Bicyclol in Preventing Drug-Induced Liver Injury in Tuberculosis Patients with Liver Disease. The International Journal of Tuberculosis and Lung Disease, 2015; 19(4): 475-480.
GRAY EL, GOLDBERG HF. Testes de função hepática anormais na linha de base são mais importantes que a idade no desenvolvimento de hepatotoxicidade induzida por isoniazida para pacientes que recebem terapia preventiva para infecção latente por tuberculose: isoniazida para tuberculose latente. Revista de Medicina Interna, 2016; 46(3): 281-287.
HASANAIN AFA, et al. Cholecalciferol for Prophylaxis against Antituberculosis Therapy-Induced Liver Disorders among Naïve Patients with Pulmonary Tuberculosis: A Randomized, Comparative Study. International Journal of Mycobacteriology, 2017; 6(2): 149-150.
HATAMKHANI S, et al. Carnitina para a Prevenção da Hepatotoxicidade Induzida por Medicamentos Antituberculose: Um Ensaio Clínico Randomizado: Antituberculose e Hepatotoxicidade. Jornal de Gastroenterologia e Hepatologia, 2014; 29(5): 997-1004.
HORITA N, et al. Decreased Activities of Daily Living Is a Strong Risk Factor for Liver Injury by Anti-Tuberculosis Drugs: Poor ADL Predicts TB Drugs Liver Injury. Respirology, 2013; 18(3): 474-479.
LUANGCHOSIRI C, et al. A Double-Blinded Randomized Controlled Trial of Silymarin for the Prevention of Antituberculosis Drug-Induced Liver Injury. BMC Complementary and Alternative Medicine, 2015; 15(1): 334-335.
MACIEL ELN, et al. Tuberculose e coronavírus: o que sabemos?. Epidemiologia e Serviços de Saúde, 2020; 29(2): e2020128-e2020129.
MADDAHI SZ, et al. A eficácia do xarope de jujuba na prevenção da hepatotoxicidade induzida por drogas em pacientes com tuberculose pulmonar: um ensaio clínico piloto randomizado duplo-cego controlado por placebo. Pesquisa em Farmacologia e Perspectivas, 2022; 10(1): e00902-e00908.
MOOSA MS, et al. A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-Tuberculosis Drug–Induced Liver Injury. Clinical Infectious Diseases, 2021; 73(9): e3377-e3383.
NAIDOO K, et al. High Rates of Drug-Induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial. Clinical Infectious Diseases, 2020; 70(12): 2675-2682.
NGONGONDO M, et al. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2018; 78(1): 54-61.
SINGH AK, et al. Appropriate Chemopreventive Strategy for Anti-Tubercular Therapy Related Liver Injury Is Unsettled: Results from a Systematic Review and Network Meta-Analysis. Expert Review of Clinical Pharmacology, 2020; 13(11): 1253-1262.
SOTGIU G, et al. The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. European Respiratory Journal, 2016; 48(4): 963-971.
TAO L, et al. Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials. Canadian Journal of Gastroenterology and Hepatology, 2019; 2019: 1-11.
TEDLA Z, et al. Hepatite Associada à Isoniazida em Adultos Infectados com HIV Recebendo 36 Meses de Profilaxia com Isoniazida no Botswana. Peito, 2015; 147(5): 1376-1384.
WU S, et al. Polimorfismos genéticos da glutationa S-transferase P1 (GSTP1) e a incidência de hepatotoxicidade induzida por drogas anti-tuberculose. PLoS One, 2016; 11(6): e0157478-e0157489.
XIONG KE, et al. Lactobacillus Casei Alleviated the Abnormal Increase of Cholestasis‐Related Liver Indices During Tuberculosis Treatment: A Post Hoc Analysis of Randomized Controlled Trial. Molecular Nutrition & Food Research, 2021; 65(16): 2100108-2100109.
ZHANG S, et al. Preventive Use of a Hepatoprotectant against Anti‐tuberculosis Drug‐induced Liver Injury: A Randomized Controlled Trial. Journal of Gastroenterology and Hepatology, 2016; 31(2): 409-416.
ZUBERI BF, et al. Comparison of British Thoracic Society and American Thoracic Society Reintroduction Guidelines for Anti-Tuberculous Therapy Induced Liver Injury. The Journal of the Pakistan Medical Association, 2014; 64(8): 896-899.